Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability

Topcu, Atakan; Mursaloglu, H.; Yalçınkaya, Y.; Karakurt, Sait; Yağız, Burcu; Alaca, Zeynep; Demir, Meryem; Coşkun, Belkıs Nihan; Dalkılıç, Ediz; İnanç, Nevsun

doi:10.1007/s10067-021-05693-9

Cited by 6 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topcu et al highlighted that symptom-related patient-reported outcome measures could be used to evaluate health-related quality of life in RA-ILD. However, they may not be very helpful in differentiating ‘ILD’ from ‘non-ILD’ causes in patients complaining respiratory symptoms, such as cough or dyspnea ( 180 ). On the other hand, concomitant comorbidities and complications due to the systemic disease involvement can represent confounding factors when assessing ILD severity ( 181 ).…”

Section: Lung Function Tests In Ra-ildmentioning

confidence: 99%

Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review

et al. 2023

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovitis as the most common clinical manifestation, and interstitial lung disease (RA-ILD) represents one of the most common and potentially severe extra-articular features. Our current understanding of the mechanisms and predictors of RA-ILD is limited despite the demonstration that an early identification of progressive fibrosing forms is crucial to provide timely treatment with antifibrotic therapies. While high resolution computed tomography is the gold standard technique for the diagnosis and follow-up of RA-ILD, it has been hypothesized that serum biomarkers (including novel and rare autoantibodies), new imaging techniques such as ultrasound of the lung, or the application of innovative radiologic algorithms may help towards predicting and detecting early forms of diseases. Further, while new treatments are becoming available for idiopathic and connective tissue disease-associated forms of lung fibrosis, the treatment of RA-ILD remains anecdotal and largely unexplored. We are convinced that a better understanding of the mechanisms connecting RA with ILD in a subgroup of patients as well as the creation of adequate diagnostic pathways will be mandatory steps for a more effective management of this clinically challenging entity.

show abstract

Section: Lung Function Tests In Ra-ildmentioning

confidence: 99%